Search

Search Constraints

You searched for: Author/Creator Watanabe, Kana

Search Results

1. Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial. Issue 1 (January 2022)

2. ChemInform Abstract: Total Syntheses of Lactonamycin (I) and Lactonamycin Z (II) with Late‐Stage A‐Ring Formation and Glycosylation. Issue 30 (4th July 2013)

5. EGFR Mutation Analysis of Circulating Tumor DNA Using an Improved PNA-LNA PCR Clamp Method. (13th July 2016)

6. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Issue 5 (May 2019)

7. Osimertinib versus osimertinib plus chemotherapy for non–small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial. (May 2021)

8. Phase II study of S-1 in patients with previously-treated invasive thymoma and thymic carcinoma: North Japan lung cancer study group trial 1203. (January 2020)

9. Possible contact transmission of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) in healthcare settings in Japan, 2020–2021. (27th September 2022)

10. Randomized Phase II Trial Comparing Carboplatin Plus Weekly Paclitaxel and Docetaxel Alone in Elderly Patients With Advanced Non-Small Cell Lung Cancer: North Japan Lung Cancer Group Trial 0801. (28th March 2014)